Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

22 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Corrigendum to "Navigating the complexity of PI3K/AKT pathway in HER-2 negative breast cancer: Biomarkers and beyond" [Crit. Rev. Oncol./Hematol. 200C (2024) 104404].
Sirico M, Jacobs F, Molinelli C, Nader-Marta G, Debien V, Dewhurst HF, Pallesch M, Merloni F, Gianni C, De Giorgi U, de Azambuja E. Sirico M, et al. Among authors: merloni f. Crit Rev Oncol Hematol. 2024 Dec;204:104542. doi: 10.1016/j.critrevonc.2024.104542. Epub 2024 Nov 4. Crit Rev Oncol Hematol. 2024. PMID: 39500669 No abstract available.
Corrigendum to "Neoadjuvant endocrine therapy for luminal breast tumors: State of the art, challenges and future perspectives" [Crit. Rev. Oncol./Hematol. 181 (2023) 103900].
Sirico M, Virga A, Conte B, Urbini M, Ulivi P, Gianni C, Merloni F, Palleschi M, Gasperoni M, Curcio A, Saha D, Buono G, Muñoz M, De Giorgi U, Schettini F. Sirico M, et al. Among authors: merloni f. Crit Rev Oncol Hematol. 2024 Aug;200:104308. doi: 10.1016/j.critrevonc.2024.104308. Epub 2024 Jun 13. Crit Rev Oncol Hematol. 2024. PMID: 38876959 Free article. No abstract available.
Oligometastatic breast cancer and metastasis-directed treatment: an aggressive multimodal approach to reach the cure.
Merloni F, Palleschi M, Casadei C, Romeo A, Curcio A, Casadei R, Stella F, Ercolani G, Gianni C, Sirico M, Cima S, Sarti S, Cecconetto L, Di Menna G, De Giorgi U. Merloni F, et al. Ther Adv Med Oncol. 2023 Mar 18;15:17588359231161412. doi: 10.1177/17588359231161412. eCollection 2023. Ther Adv Med Oncol. 2023. PMID: 36950272 Free PMC article. Review.
Locoregional treatment of de novo stage IV breast cancer in the era of modern oncology.
Merloni F, Palleschi M, Gianni C, Casadei C, Curcio A, Romeo A, Rocchi M, Cima S, Sirico M, Sarti S, Cecconetto L, Mariotti M, Di Menna G, De Giorgi U. Merloni F, et al. Front Oncol. 2023 Jan 30;13:1083297. doi: 10.3389/fonc.2023.1083297. eCollection 2023. Front Oncol. 2023. PMID: 36793604 Free PMC article. Review.
Neoadjuvant endocrine therapy for luminal breast tumors: State of the art, challenges and future perspectives.
Sirico M, Virga A, Conte B, Urbini M, Ulivi P, Gianni C, Merloni F, Palleschi M, Gasperoni M, Curcio A, Saha D, Buono G, Muñoz M, De Giorgi U, Schettini F. Sirico M, et al. Among authors: merloni f. Crit Rev Oncol Hematol. 2023 Jan;181:103900. doi: 10.1016/j.critrevonc.2022.103900. Epub 2022 Dec 21. Crit Rev Oncol Hematol. 2023. PMID: 36565894 Free article. Review.
22 results